NEW YORK, December 31, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Covidien plc (NYSE: COV), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Endo Health Solutions Inc. (NASDAQ: ENDP), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Biogen Idec Inc. Research Report
On December 17, 2013, Biogen Idec Inc. (Biogen Idec) and Samsung Bioepis announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease. Biogen Idec informed that under the terms of the agreement, it will be responsible for commercialization of these product candidates across Europe, where there already exists a strong market for biosimilars and a defined regulatory pathway. Tony Kingsley, Executive Vice President of Global Commercial Operations for Biogen Idec, said, "This is a unique opportunity for us to leverage our experience in developing and manufacturing high-quality biologics in therapeutic areas where we are deeply focused, and provide medicines to patients where there is a significant societal need. As a company that aims to make a difference in the lives of patients with serious diseases, we are excited by the potential to offer additional highly effective therapies in critical areas where there is growing demand." The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Covidien plc Research Report
On December 19, 2013, Covidien plc (Covidien) announced that it will report its Q1 FY 2014 results on January 24, 2013. The Company said that it will host a conference call for investors on the same day at 8:30 a.m. ET, and interested parties may access the same through a webcast at the Company's website. According to the Company, a replay of the conference call will be available beginning at 11:30 a.m. ET on January 24, 2014, and ending at 5:00 p.m. on January 31, 2014. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Vertex Pharmaceuticals Incorporated Research Report
On December 19, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced data from a Phase 3 study of ivacaftor in 69 people 6 years of age and older with cystic fibrosis (CF) who have the R117H mutation. Vertex informed that in the study, the mean absolute treatment difference in the change from baseline in percent predicted FEV1 between treatment with ivacaftor and placebo was 2.1% percentage points (p=0.20) and the mean relative treatment difference in percent predicted FEV1 was 5.0% (p= 0.06) through the 24-week treatment period among all patients (intent-to-treat analysis). The Company added that the study did not meet its primary endpoint of the absolute change from baseline FEV1 (percent predicted forced expiratory volume in one second, FEV1) throughout the treatment period for ivacaftor compared to placebo across all patients. Lastly, Vertex informed that a pre-specified subset analysis in patients 18 years of age and older (n=50) showed statistically significant improvements in lung function and other key secondary endpoints. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Endo Health Solutions Inc. Research Report
On December 19, 2013, Endo Health Solutions Inc. (Endo) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act) regarding Endo's proposed acquisition of Paladin Labs Inc. (Paladin Labs) was terminated by the U.S. Federal Trade Commission on December 17, 2013. The Company stated that the Canadian Competition Bureau issued a no-action letter on December 18, 2013, which constitutes Canadian Competition Act compliance for Endo's proposed acquisition of Paladin Labs. Endo stated that the early termination of the HSR waiting period in the United States and the no-action letter obtained from the Canadian Competition Bureau in Canada satisfy conditions to the proposed acquisition. According to the Company, the proposed acquisition remains subject to certain conditions and approvals, including regulatory approvals, approval by shareholders of Endo and Paladin Labs, approval of the Superior Court of Quebec, registration and listing of New Endo shares and customary closing conditions. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Momenta Pharmaceuticals Inc. Research Report
On December 26, 2013, Momenta Pharmaceuticals Inc.'s (Momenta Pharmaceuticals) stock gained 0.68%, ending the day's trading session at $17.65. Over the previous three trading sessions, shares of Momenta Pharmaceuticals gained 1.44%, compared to the Nasdaq Composite Index which gained 1.52% during the same period. The Full Research Report on Momenta Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner